19
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Autoimmune Encephalitis Misdiagnosis in Adults

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This case series assesses the diseases misdiagnosed as autoimmune encephalitis and potential reasons for misdiagnosis.

          Key Points

          Question

          What diseases are misdiagnosed as autoimmune encephalitis and which factors contribute to misdiagnosis?

          Findings

          In this case series of 107 outpatients misdiagnosed with autoimmune encephalitis, approximately half had functional neurologic or psychiatric disorders. An insidious rather than subacute onset and lack of magnetic resonance imaging or cerebrospinal fluid findings suggestive of inflammation were clues to misdiagnosis; overinterpretation of serum nonspecific antibodies was a major contributor to misdiagnosis.

          Meaning

          A broad range of disorders are misdiagnosed as autoimmune encephalitis and misdiagnosis occurs in many settings including at specialized centers participating in this study.

          Abstract

          Importance

          Autoimmune encephalitis misdiagnosis can lead to harm.

          Objective

          To determine the diseases misdiagnosed as autoimmune encephalitis and potential reasons for misdiagnosis.

          Design, Setting, and Participants

          This retrospective multicenter study took place from January 1, 2014, to December 31, 2020, at autoimmune encephalitis subspecialty outpatient clinics including Mayo Clinic (n = 44), University of Oxford (n = 18), University of Texas Southwestern (n = 18), University of California, San Francisco (n = 17), University of Washington in St Louis (n = 6), and University of Utah (n = 4). Inclusion criteria were adults (age ≥18 years) with a prior autoimmune encephalitis diagnosis at a participating center or other medical facility and a subsequent alternative diagnosis at a participating center. A total of 393 patients were referred with an autoimmune encephalitis diagnosis, and of those, 286 patients with true autoimmune encephalitis were excluded.

          Main Outcomes and Measures

          Data were collected on clinical features, investigations, fulfillment of autoimmune encephalitis criteria, alternative diagnoses, potential contributors to misdiagnosis, and immunotherapy adverse reactions.

          Results

          A total of 107 patients were misdiagnosed with autoimmune encephalitis, and 77 (72%) did not fulfill diagnostic criteria for autoimmune encephalitis. The median (IQR) age was 48 (35.5-60.5) years and 65 (61%) were female. Correct diagnoses included functional neurologic disorder (27 [25%]), neurodegenerative disease (22 [20.5%]), primary psychiatric disease (19 [18%]), cognitive deficits from comorbidities (11 [10%]), cerebral neoplasm (10 [9.5%]), and other (18 [17%]). Onset was acute/subacute in 56 (52%) or insidious (>3 months) in 51 (48%). Magnetic resonance imaging of the brain was suggestive of encephalitis in 19 of 104 patients (18%) and cerebrospinal fluid (CSF) pleocytosis occurred in 16 of 84 patients (19%). Thyroid peroxidase antibodies were elevated in 24 of 62 patients (39%). Positive neural autoantibodies were more frequent in serum than CSF (48 of 105 [46%] vs 7 of 91 [8%]) and included 1 or more of GAD65 (n = 14), voltage-gated potassium channel complex (LGI1 and CASPR2 negative) (n = 10), N-methyl- d-aspartate receptor by cell-based assay only (n = 10; 6 negative in CSF), and other (n = 18). Adverse reactions from immunotherapies occurred in 17 of 84 patients (20%). Potential contributors to misdiagnosis included overinterpretation of positive serum antibodies (53 [50%]), misinterpretation of functional/psychiatric, or nonspecific cognitive dysfunction as encephalopathy (41 [38%]).

          Conclusions and Relevance

          When evaluating for autoimmune encephalitis, a broad differential diagnosis should be considered and misdiagnosis occurs in many settings including at specialized centers. In this study, red flags suggesting alternative diagnoses included an insidious onset, positive nonspecific serum antibody, and failure to fulfill autoimmune encephalitis diagnostic criteria. Autoimmune encephalitis misdiagnosis leads to morbidity from unnecessary immunotherapies and delayed treatment of the correct diagnosis.

          Related collections

          Most cited references58

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

          In 2011, the National Institute on Aging and Alzheimer’s Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer’s disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer’s Association to update and unify the 2011 guidelines. This unifying update is labeled a “research framework” because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer’s Association Research Framework, Alzheimer’s disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker-based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A clinical approach to diagnosis of autoimmune encephalitis.

            Encephalitis is a severe inflammatory disorder of the brain with many possible causes and a complex differential diagnosis. Advances in autoimmune encephalitis research in the past 10 years have led to the identification of new syndromes and biomarkers that have transformed the diagnostic approach to these disorders. However, existing criteria for autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy, which might delay the diagnosis. We reviewed the literature and gathered the experience of a team of experts with the aims of developing a practical, syndrome-based diagnostic approach to autoimmune encephalitis and providing guidelines to navigate through the differential diagnosis. Because autoantibody test results and response to therapy are not available at disease onset, we based the initial diagnostic approach on neurological assessment and conventional tests that are accessible to most clinicians. Through logical differential diagnosis, levels of evidence for autoimmune encephalitis (possible, probable, or definite) are achieved, which can lead to prompt immunotherapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

              NHANES III measured serum TSH, total serum T(4), antithyroperoxidase (TPOAb), and antithyroglobulin (TgAb) antibodies from a sample of 17,353 people aged > or =12 yr representing the geographic and ethnic distribution of the U.S. population. These data provide a reference for other studies of these analytes in the U.S. For the 16,533 people who did not report thyroid disease, goiter, or taking thyroid medications (disease-free population), we determined mean concentrations of TSH, T(4), TgAb, and TPOAb. A reference population of 13,344 people was selected from the disease-free population by excluding, in addition, those who were pregnant, taking androgens or estrogens, who had thyroid antibodies, or biochemical hypothyroidism or hyperthyroidism. The influence of demographics on TSH, T(4), and antibodies was examined. Hypothyroidism was found in 4.6% of the U.S. population (0.3% clinical and 4.3% subclinical) and hyperthyroidism in 1.3% (0.5% clinical and 0.7% subclinical). (Subclinical hypothyroidism is used in this paper to mean mild hypothyroidism, the term now preferred by the American Thyroid Association for the laboratory findings described.) For the disease-free population, mean serum TSH was 1.50 (95% confidence interval, 1.46-1.54) mIU/liter, was higher in females than males, and higher in white non-Hispanics (whites) [1.57 (1.52-1.62) mIU/liter] than black non-Hispanics (blacks) [1.18 (1.14-1.21) mIU/liter] (P < 0.001) or Mexican Americans [1.43 (1.40-1.46) mIU/liter] (P < 0.001). TgAb were positive in 10.4 +/- 0.5% and TPOAb, in 11.3 +/- 0.4%; positive antibodies were more prevalent in women than men, increased with age, and TPOAb were less prevalent in blacks (4.5 +/- 0.3%) than in whites (12.3 +/- 0.5%) (P < 0.001). TPOAb were significantly associated with hypo or hyperthyroidism, but TgAb were not. Using the reference population, geometric mean TSH was 1.40 +/- 0.02 mIU/liter and increased with age, and was significantly lower in blacks (1.18 +/- 0.02 mIU/liter) than whites (1.45 +/- 0.02 mIU/liter) (P < 0.001) and Mexican Americans (1.37 +/- 0.02 mIU/liter) (P < 0.001). Arithmetic mean total T(4) was 112.3 +/- 0.7 nmol/liter in the disease-free population and was consistently higher among Mexican Americans in all populations. In the reference population, mean total T(4) in Mexican Americans was (116.3 +/- 0.7 nmol/liter), significantly higher than whites (110.0 +/- 0.8 nmol/liter) or blacks (109.4 +/- 0.8 nmol/liter) (P < 0.0001). The difference persisted in all age groups. In summary, TSH and the prevalence of antithyroid antibodies are greater in females, increase with age, and are greater in whites and Mexican Americans than in blacks. TgAb alone in the absence of TPOAb is not significantly associated with thyroid disease. The lower prevalence of thyroid antibodies and lower TSH concentrations in blacks need more research to relate these findings to clinical status. A large proportion of the U.S. population unknowingly have laboratory evidence of thyroid disease, which supports the usefulness of screening for early detection.
                Bookmark

                Author and article information

                Journal
                JAMA Neurol
                JAMA Neurol
                JAMA Neurology
                American Medical Association
                2168-6149
                2168-6157
                28 November 2022
                January 2023
                28 November 2022
                : 80
                : 1
                : 30-39
                Affiliations
                [1 ]Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
                [2 ]Center for Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
                [3 ]Department of Neurology, University of California, San Francisco (UCSF), San Francisco
                [4 ]Department of Neurology, Mayo Clinic, Jacksonville, Florida
                [5 ]Department of Neurology, University of Texas Southwestern Medical Center, Dallas
                [6 ]Autoimmune Neurology Group, West Wing, Level 3, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
                [7 ]Movement Disorders Unit, Department of Neurology, Tel Aviv Sourazky Medical Center, Affiliate of Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
                [8 ]Washington University in St Louis, St Louis, Missouri
                [9 ]Department of Neurology, University of Utah, Salt Lake City
                [10 ]Larner College of Medicine at the University of Vermont, Burlington
                [11 ]Graduate School of Health Sciences, Mayo Clinic College of Medicine, Rochester, Minnesota
                Author notes
                Article Information
                Accepted for Publication: September 22, 2022.
                Published Online: November 28, 2022. doi:10.1001/jamaneurol.2022.4251
                Corresponding Author: Eoin P. Flanagan, MD, Mayo Clinic College of Medicine, Rochester, MN 55905 ( flanagan.eoin@ 123456mayo.edu ).
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Flanagan EP et al. JAMA Neurology.
                Author Contributions: Dr Flanagan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. These authors contributed equally: Drs Geschwind, Irani, and Vernino.
                Concept and design: Flanagan, Lopez Chiriboga, Blackburn, Gelfand.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Flanagan, Lopez Chiriboga, Rodenbeck, Solomon, Irani.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Flanagan.
                Administrative, technical, or material support: Lopez Chiriboga, Blackburn, Binks, Zitser, Vernino, Irani.
                Supervision: Flanagan, Geschwind, Vernino, Irani.
                Conflict of Interest Disclosures: Dr Flanagan has served on advisory boards for Alexion, Genentech, UCB, and Horizon Therapeutics outside the submitted work; has a patent for DACH1-IgG as a biomarker of paraneoplastic autoimmunity pending; has received speaker honoraria from Pharmacy Times; has received royalties from UpToDate; was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics; has received funding from the National Institutes of Health (grant R01NS113828); is a member of the medical advisory board of the MOG project; and is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. Dr Geschwind reported grants from the National Institute on Aging (grants R01 AG031189, R56 AG055619, and R01 AG062562) and research support from Michael J. Homer Family Fund during the conduct of the study; personal fees from MedConnect Pro LLC Medical Legal, Clarion, Blade Therapeutics, Clearview Healthcare Partners, LifeSci Capital LLC, Ascel Health LLC, Teledoc Health Inc, Microvention Terumo, Reata Pharmaceuticals, Wolters Kluwer, Maupin Cox, Wallace & Milsap LLC, Trinity Partners LLC, Anderson Boutwell Traylor, and Adept Field; nonfinancial support from Ionis Pharmaceuticals; has consulted for Best Doctors Inc, Biohaven Pharma Inc, Bioscience Pharma Partners, LLC, First Thought Consulting, Grand Rounds Inc/UCSF Second Opinion Inc, Quest Diagnostics, and Smith & Hennessey LLC; has received speaking honoraria from Oakstone Publishing; has received research support from Alliance Biosecure, CurePSP, the Tau Consortium, Quest Diagnostics, and the National Institutes of Health; and serves on the board of directors for San Francisco Bay Area Physicians for Social Responsibility and on the editorial board of Dementia & Neuropsychologia. Dr Lopez-Chiriboga has served on advisory boards for Genentech and Horizon Therapeutics. Dr Blackburn reported personal fees from Genentech, grants from Siegel Rare Neuroimmune Association outside the submitted work. Dr Binks reported grants from Wellcome Trust during the conduct of the study and had a patent for Ref. JA94536P.GBA pending (diagnostic strategy to improve specificity of CASPR2 antibody detection). Dr Gelfand reported grants from Genentech/Roche for research support to University of California, San Francisco for clinical trials; service on trial steering committees and grants from Vigil Neuroscience for research support to University of California, San Francisco for clinical research study; and personal fees from Biogen for consulting outside the submitted work. Dr Day reported grants from National Institute on Aging (grant K23AG064029) during the conduct of the study; personal fees from PeerView Media, Continuing Education, DynaMed, and Parabon Nanolabs outside the submitted work; is co–principal investigator of the ExTINGUISH Trial (1U01NS120901); owns stock (>$10 000) in ANI Pharmaceuticals; and is the clinical director of the Anti-NMDA Receptor Encephalitis Foundation (uncompensated). Dr Clardy reported being site investigator for an Alexion clinical trial; grants from National Institute of Neurological Disorders and Stroke for the ExTINGUISH Trial, Western Institute for Veteran Research, and Sumaira Foundation for NMO; research support from Siegel Rare Neuroimmune Association Funding and Barbara Gural Steinmetz Foundation Funding; personal fees from American Academy of Neurology (section editor, Neurology Podcast and Neurology Minute), from Alexion, VielaBio/Horizon, Genentech/Roche, Guidepoint, ExpertConnect, and Clarion Healthcare (majority fees to University of Utah); and funding from Viela Bio/Horizon and Alexion/AstraZeneca outside the submitted work. Dr Solomon reported research funding from Bristol Myers Squibb; consulting and nonpromotional speaking for EMD Serono; personal fees from Genentech, Biogen, Alexion, Celgene, Greenwich Bioscience, and Octave Biosciences; expert witness testimony for Jacob D. Fuchsberg Law Firm and Koskoff, Koskoff, and Bieder; served on advisory board of Genentech, Biogen, Alexion, Celgene, Greenwich Biosciences, and TG Therapeutics; and conducted contract research for Sanofi, Biogen, Novartis, Actelion, and Genetech outside the submitted work. Dr Pittock reported grants, personal fees, and nonfinancial support from Alexion and MedImmune/Viela Bio/Horizon (all compensation is paid directly to the Mayo Clinic); grants from the National Institutes of Health, Grifols, NovelMed, and F. Hoffmann-LaRoche/Roche/Genentech (all compensation is paid directly to Mayo Clinic); consulting for Astellas (compensation to Mayo Clinic and personal compensation); personal fees from Sage Therapeutics, UCB, and F. Hoffmann-LaRoche/Roche/Genentech; and had patent #8,889,102 issued, patent #9,891,219B2 issued, and a patent for GFAP-IgG; Septin-5-IgG; MAP1B-IgG; Kelch-like protein 11; PDE10A pending. Dr McKeon reported grants from the National Institutes of Health (grants RO1NS126227 and U01NS120901) during the conduct of the study; consulting fees from Janssen and Roche (all paid to Mayo Clinic) outside the submitted work; and had a patent for MAP1B antibody issued, a patent for Septins 5, 7, GFAP, PDE10A, KLCHL11 antibodies pending, a patent for Septin antibodies licensed, and a patent for MAP1B antibodies with royalties paid. Dr Dubey reported a patent for KLHL11 pending, a patent for LUZP4 pending, and a patent for CAVIN4 pending; and has consulted for UCB, Astellas, Argenx, Immunovant and Arialys pharmaceuticals (all compensation paid directly to Mayo Clinic). Dr Zekeridou reported grants from Roche/Genentech outside the submitted work and had a patent for DACH1-IgG as biomarker of neurological autoimmunity pending and a patent for PDE10A-IgG as biomarker of neurological autoimmunity pending. Dr Vernino has served as a consultant for Alterity, Argenx, Catalyst, Genentech, and Sage Therapeutics and has received research support from Dysautonomia International, BioHaven, Grifols, and Quest Diagnostics (through a licensing contract). Dr Irani reported grants from UCB, CSL Behring, and ONO Pharmaceuticals outside the submitted work; had a patent for LGI1/Caspr2 antibodies with royalties paid from EIAG, a patent for Autoantibody diagnostics issued, and a patent for Relapse predictions pending; and honoraria/research support from UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharmaceuticals. No other disclosures were reported.
                Funding/Support: Dr Binks is supported by the Wellcome Trust, has had salary support from the National Institute for Health Research ( NIHR), and holds grants from PetSavers (03.20) and Petplan Charitable Trust (grant S20-924-963). Dr Geschwind was supported by the National Institute on Aging (grants R01 AG AG031189; R01AG062562; R56 AG055619) and the Michael J. Homer Family Fund. Dr Irani is supported by a Medical Research Council Fellowship (MR/V007173/1), Wellcome Trust (grant 104079/Z/14/Z), BMA Research Grants- Vera Down grant (2013) and Margaret Temple (2017), Epilepsy Research UK (P1201), the Fulbright UK-US commission (MS-Society research award) and by the NIHR Oxford Biomedical Research Centre.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health and Care Research, or the Department of Health.
                Additional Contributions: We thank Jessica Sagen, MA (Mayo Clinic, Rochester, Minnesota), and Michael Terranova, MS (University of California San Francisco), for their administrative assistance; compensation was not received.
                Article
                noi220078
                10.1001/jamaneurol.2022.4251
                9706400
                36441519
                48aa09ad-8549-4043-9f46-8856039cad60
                Copyright 2022 Flanagan EP et al. JAMA Neurology.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 25 May 2022
                : 22 September 2022
                Funding
                Funded by: Wellcome Trust
                Funded by: National Institute for Health Research
                Funded by: NIHR
                Funded by: PetSavers
                Funded by: Petplan Charitable Trust
                Funded by: National Institute on Aging
                Funded by: Michael J. Homer Family Fund
                Funded by: Medical Research Council
                Funded by: Wellcome Trust
                Funded by: BMA
                Funded by: Margaret Temple
                Funded by: Epilepsy Research UK
                Funded by: Fulbright UK-US commission
                Funded by: Oxford Biomedical Research Centre
                Categories
                Research
                Research
                Original Investigation
                Online First
                Comments

                Comments

                Comment on this article